Phase 3 N=60 Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
Bipolar Disorder
Primary: Time in Weeks to Discontinuation — 25.93; 3.00 time in weeks to discontinuation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Localized Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…
Phase 2 N=74 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 24; 29 participants
Phase 2 N=134 S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Stage IV Pancreatic Cancer
Primary: Maximum Tolerated Dose Determination — 6 mg/kg IMC-A12
Phase 3 N=260 A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
Chronic Obstructive Pulmonary Disease
Primary: Clinical Laboratory Test: Haematology -Erythrocytes — -7.6; -0.1 *10000/μl
N/A N=354 Triathlon® Posteriorly Stabilized (PS) Total Knee System - Outcomes Study
Arthroplasty, Replacement, Knee
Primary: Range of Motion — 124 degrees
Phase 4 N=1,053 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis
Primary: Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6 — 22.5; 3.5 units on a scale
Phase 3 N=393 Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Lymphoma
Primary: Event-free Survival — 88; 82; 80; 63 percentage of particpants — p=.97
Phase 2 N=19 Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage IV Pancreatic Cancer
Primary: Six Month Survival — 11 percentage of patients
Phase 2 N=273 Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
Obesity
Primary: LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable…
Phase 3 N=289 Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients
Postpartum Anemia
Primary: Number of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL — 127; 98…
Phase 2 N=22 Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
Hormone Refractory Prostate Cancer · Recurrent Prostate Cancer
Primary: 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2) — 2; 8 participants
Phase 1 N=21 Sildenafil in Single Ventricle Patients
Heart Disease
Primary: Maximum Sildenafil Plasma Concentration — 181; 515; 545; 202 ng/mL
Phase 4 N=219 Switching Medication to Treat Schizophrenia
Schizophrenia
Primary: Number Who Discontinued Medication Within First 6 Study Months — 11; 23 participants
Phase 3 N=146 Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM
Diabetes Mellitus, Type 1
Primary: Number of Participants With a Decrease >=0.5% HbA1c With no Severe Hypoglycemic Events — 13; 19 participants